Peer Review History

Original SubmissionJune 18, 2019
Decision Letter - John Matthew Koomen, Editor

PONE-D-19-17238

Development and Validation of LC-MS/MS Method for Imatinib and Norimatinib Monitoring by Finger-prick DBS in Gastrointestinal Stromal Tumor Patients

PLOS ONE

Dear Dr. Posocco,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

We would appreciate receiving your revised manuscript by Oct 05 2019 11:59PM. When you are ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled 'Manuscript'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

John Matthew Koomen, PhD

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2.  In your Methods section, please provide additional information about the participant recruitment method and the demographic details of your participants. Please ensure you have provided sufficient details to replicate the analyses such as: a) the recruitment date range (month and year), b) a description of any inclusion/exclusion criteria that were applied to participant recruitment, c) a table of relevant demographic details, and d) a description of how participants were recruited.

3. Please provide a justification of the sample size used in this study.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Minor editing for English grammar and usage. Line 104 should have a reference. Which model Millipore was used to produce water in line 135. Working solutions and calibrators are claimed to be made "from A to L", however only ten working solutions and calibrators were identified (Lines 150, 152, 161 & 163). Line 345 states that the clinical protocol was designed to collect blood "without anticoagulant", however lines 319 & 320 state that in the clinical protocol, venous blood was collected with K-EDTA, an anti-coagulant. Was a separate vacutainer collected for the correlation between finger prick and venous collection? Line 505, indicate "LCCC" stands for Lin’s Concordance Correlation Coefficient. Typo on Line 542 "LC-M/MS"

Reviewer #2: I think the article is well written in a straightforward manner, thus easy to follow by the readers. The validation experiments done by the authors are comprehensive and sufficient.

There are only a few minor revisions/addendum:

L152, 159-163: There is some error in listing of quality control concentrations, the final concentrations do not add up from the working concentrations. It is suggested to keep the order of concentrations consistent, best listed in an ascending manner.

L301-304: The HPLC parameters changed from the method development (L186-189) to the plasma sample analysis. Please discuss why it has changed and the effects it brought. Normally, the method validated should be kept the same in GLP conditions.

L449: change “follow” to “follows”

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Samer Sansil

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files to be viewed.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1:

Minor editing for English grammar and usage.

The manuscript has been revised for English grammar.

Line 104 should have a reference.

As properly suggested by Reviewer, a reference has been added to line 104 related to the advantages of DBS in TDM practice.

Which model Millipore was used to produce water in line 135.

The Millipore model used was Milli-Q® IQ 7000. This information has been added to the manuscript (Line 130).

Working solutions and calibrators are claimed to be made "from A to L", however only ten working solutions and calibrators were identified (Lines 150, 152, 161 & 163).

The Reviewer is perfectly right since the Italian alphabet was mistakenly used to name the working solutions (thus from A to L we have only 10 letters). The manuscript has been revised according to the English alphabet (thus the working solutions are now named from A to J).

Line 345 states that the clinical protocol was designed to collect blood "without anticoagulant", however lines 319 & 320 state that in the clinical protocol, venous blood was collected with K-EDTA, an anti-coagulant. Was a separate vacutainer collected for the correlation between finger prick and venous collection?

The Reviewer is right since the description of samples collection (Line 318-328) was erroneously reported. In fact, 1 mL of venous blood was collected without anticoagulant using a syringe and directly transferred into 1.5 mL tube. The blood was immediately spotted with a Gilson pipette on a piece of Whatman ET31CHR filter paper to make Control – DBS (the spots were 20 µL in volume). This step needed to be fast to avoid blood coagulation inside the tubes. The chapter has been properly corrected.

Line 505, indicate "LCCC" stands for Lin’s Concordance Correlation Coefficient.

The LCCC abbreviation was introduced at the first mention of Lin’s concordance correlation coefficient (Line 373). Anyway it could be easier for the reader to make explicit what LCCC stands for also in Line 505 since it is an uncommon abbreviation.

Typo on Line 542 "LC-M/MS"

We thank the reviewer for finding this typo that has been corrected.

Reviewer #2:

I think the article is well written in a straightforward manner, thus easy to follow by the readers. The validation experiments done by the authors are comprehensive and sufficient. There are only a few minor revisions/addendum:

L152, 159-163: There is some error in listing of quality control concentrations, the final concentrations do not add up from the working concentrations. It is suggested to keep the order of concentrations consistent, best listed in an ascending manner.

We thank the reviewer for finding the error in quality control concentrations reported in Line 152 that have been substituted with the correct ones (120, 25,5 µg/mL).

L301-304: The HPLC parameters changed from the method development (L186-189) to the plasma sample analysis. Please discuss why it has changed and the effects it brought. Normally, the method validated should be kept the same in GLP conditions.

The LC-MS/MS method applied for the quantification of IMA and norIMA in patients plasma sample was already in use in our laboratory (it is currently under revision by Journal of Pharmaceutical and Biomedical Analysis with the following title: “A New High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Therapeutic Drug Monitoring of Imatinib and Norimatinib in GIST patients“). It was developed and validated according to FDA and EMA guidelines before the development of the assay for the quantification of DBS samples and thus it was used as REFERENCE method during the cross validation study (Line 294-295). DBS samples were analysed with the proposed method (COMPARANTOR method) while plasma samples were analysed with the reference method: the respective results were finally compared applying statistical analyses such as Passing-Bablok regression, Bland-Altman method, Lin’s concordance correlation coefficient and FDA/EMA requirements.

L449: change “follow” to “follows”

Done.

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - John Matthew Koomen, Editor

Development and Validation of LC-MS/MS Method for Imatinib and Norimatinib Monitoring by Finger-prick DBS in Gastrointestinal Stromal Tumor Patients

PONE-D-19-17238R1

Dear Dr. Posocco,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at https://www.editorialmanager.com/pone/, click the "Update My Information" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

With kind regards,

John Matthew Koomen, PhD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Thank you for addressing my comments. You are correct that Line 373 already states the abbreviation and thus, does not need to be repeated. The change does make it easier for the reader.

Reviewer #2: The authors have addressed the reviewers' concerns satisfactorily and in my opinion, should proceed for acceptance.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Samer Sansil

Reviewer #2: No

Formally Accepted
Acceptance Letter - John Matthew Koomen, Editor

PONE-D-19-17238R1

Development and Validation of LC-MS/MS Method for Imatinib and Norimatinib Monitoring by Finger-prick DBS in Gastrointestinal Stromal Tumor Patients

Dear Dr. Posocco:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

For any other questions or concerns, please email plosone@plos.org.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. John Matthew Koomen

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .